The presence of preexisting (memory) or de novo donor‐specific HLA antibodies (DSAs) is a
known barrier to successful long‐term organ transplantation. Yet, despite the fact that …

The purpose of the STAR 2019 Working Group was to build on findings from the initial STAR
report to further clarify the expectations, limitations, perceptions, and utility of alloimmune …

Abstract Although anti–HLA (Human Leukocyte Antigen) donor-specific antibodies (DSAs)
are commonly measured in clinical practice and their relationship with transplant outcome is …

Abstract The Sensitization in Transplantation: Assessment of Risk workgroup is a
collaborative effort of the American Society of Transplantation and the American Society of …

Panel-reactive antibodies are widely regarded as an important immunological risk factor for
rejection and graft loss. The broadness of sensitization against HLA is most appropriately …

De novo donor-specific HLA antibodies (dnDSA) are recognized as a risk factor for
premature allograft failure. Determinants of DSA specificity are generated via the indirect …

The development of de novo donor-specific HLA antibodies (dnDSA) after transplantation is
associated with graft failure, mortality, and cost. There is no effective therapeutic intervention …

Human leukocyte antigen (HLA) compatibility is very important for successful transplantation
of solid organs. In this paper, we focused on the humoral arm of immunity in the clinical …

OBJECTIVE: HLA alloimmunization is caused by various sensitization events, such as
transfusion, pregnancy, or organ transplantation. However, the effects of a particular …

Background. Since the landmark studies of Patel and Terasaki in the late 1960s,
pretransplant cross-matching has been performed by HLA laboratories on a 24-hr/7-day …